Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Placental growth factor mediates mesenchymal cell development, cartilage turnover, and bone remodeling during fracture repair.
Maes C, Coenegrachts L, Stockmans I, Daci E, Luttun A, Petryk A, Gopalakrishnan R, Moermans K, Smets N, Verfaillie CM, Carmeliet P, Bouillon R, Carmeliet G. Maes C, et al. Among authors: coenegrachts l. J Clin Invest. 2006 May;116(5):1230-42. doi: 10.1172/JCI26772. Epub 2006 Apr 13. J Clin Invest. 2006. PMID: 16614757 Free PMC article.
Increased skeletal VEGF enhances beta-catenin activity and results in excessively ossified bones.
Maes C, Goossens S, Bartunkova S, Drogat B, Coenegrachts L, Stockmans I, Moermans K, Nyabi O, Haigh K, Naessens M, Haenebalcke L, Tuckermann JP, Tjwa M, Carmeliet P, Mandic V, David JP, Behrens A, Nagy A, Carmeliet G, Haigh JJ. Maes C, et al. Among authors: coenegrachts l. EMBO J. 2010 Jan 20;29(2):424-41. doi: 10.1038/emboj.2009.361. Epub 2009 Dec 10. EMBO J. 2010. PMID: 20010698 Free PMC article.
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease.
Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T, Loges S, Albrecht I, Jonckx B, Vinckier S, Van Steenkiste C, Tugues S, Rolny C, De Mol M, Dettori D, Hainaud P, Coenegrachts L, Contreres JO, Van Bergen T, Cuervo H, Xiao WH, Le Henaff C, Buysschaert I, Kharabi Masouleh B, Geerts A, Schomber T, Bonnin P, Lambert V, Haustraete J, Zacchigna S, Rakic JM, Jiménez W, Noël A, Giacca M, Colle I, Foidart JM, Tobelem G, Morales-Ruiz M, Vilar J, Maxwell P, Vinores SA, Carmeliet G, Dewerchin M, Claesson-Welsh L, Dupuy E, Van Vlierberghe H, Christofori G, Mazzone M, Detmar M, Collen D, Carmeliet P. Van de Veire S, et al. Among authors: coenegrachts l. Cell. 2010 Apr 2;141(1):178-90. doi: 10.1016/j.cell.2010.02.039. Cell. 2010. PMID: 20371353 Free article.
Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
Schrauwen S, Depreeuw J, Coenegrachts L, Hermans E, Lambrechts D, Amant F. Schrauwen S, et al. Among authors: coenegrachts l. Gynecol Oncol. 2015 Jul;138(1):165-73. doi: 10.1016/j.ygyno.2015.04.028. Epub 2015 Apr 28. Gynecol Oncol. 2015. PMID: 25933683 Free article.
High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
Garcia-Dios DA, Lambrechts D, Coenegrachts L, Vandenput I, Capoen A, Webb PM, Ferguson K; ANECS; Akslen LA, Claes B, Vergote I, Moerman P, Van Robays J, Marcickiewicz J, Salvesen HB, Spurdle AB, Amant F. Garcia-Dios DA, et al. Among authors: coenegrachts l. Gynecol Oncol. 2013 Feb;128(2):327-34. doi: 10.1016/j.ygyno.2012.11.037. Epub 2012 Dec 4. Gynecol Oncol. 2013. PMID: 23219661
22 results